Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company that applies a unique approach to gene science based on Nobel Prize-winning technology to pioneer medicines that transform patients' lives. Founded in 1995 in The Woodlands, Texas as Lexicon Genetics, the company has spent three decades translating genetic insights into innovative therapies. Lexicon's therapeutic focus spans neuropathic pain and cardiometabolic disease, and the company is advancing its lead candidate pilavapadin into Phase 3 trials. Lexicon trades publicly on Nasdaq under the ticker LXRX.